Rociletinib is a medication developed to treat non-small cell lung carcinomas with a specific mutation. It is a third-generation

epidermal growth factor receptor The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is a transmembrane protein that is a receptor for members of the epidermal growth factor family (EGF family) of extracellular protein ligands. The epidermal growth factor recept ...

tyrosine kinase inhibitor. It was being developed by

Clovis Oncology Clovis Oncology is an American pharmaceutical company which mainly markets products for treatment in oncology. Clovis was founded in 2009 and is headquartered in Boulder, Colorado. The company is a publicly traded company on NASDAQ under the ...

as a potential treatment for non-small-cell lung cancer. In May 2016, development of rociletinib was halted, along with its associated clinical trials, and Clovis Oncology withdrew its

marketing authorisation application Marketing Authorisation Application (MAA) is an application submitted by a drug manufacturer seeking marketing authorisation, that is permission to bring a medicinal product (for example, a new medicine or generic medicine) to the market. MAA is pa ...

from the

European Medicines Agency The European Medicines Agency (EMA) is an agency of the European Union (EU) in charge of the evaluation and supervision of medicinal products. Prior to 2004, it was known as the European Agency for the Evaluation of Medicinal Products or Euro ...

References

Acrylamides Experimental cancer drugs Trifluoromethyl compounds Receptor tyrosine kinase inhibitors Abandoned drugs {{antineoplastic-drug-stub